Xiaoming Hou

Lanzhou, CN 
Lanzhou, CN 

Overview

Xiaoming Hou practices practicing medicine in Lanzhou, China.

Their clinical expertise encompasses Bile Acid Malabsorption, Radiation Enteritis, Non-Small Cell Lung Cancer (NSCLC), and Wiskott-Aldrich Syndrome.

They are actively involved in clinical research, co-authoring 29 peer reviewed articles and participating in 1 clinical trial.

Locations

Lanzhou, China
Other Locations
Tianjin, 300457, China
P.R. China, Shijiazhuang, 050000, China
Beijing, 100853, China
Xinjiang, 830054, China

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Experts who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

1 Clinical Trials

A Randomized, Multicenter, Phase 3 Study of Zanidatamab in Combination With Chemotherapy With or Without Tislelizumab in Subjects With HER2-positive Unresectable Locally Advanced or Metastatic Gastroesophageal Adenocarcinoma (GEA)
A Randomized, Multicenter, Phase 3 Study of Zanidatamab in Combination With Chemotherapy With or Without Tislelizumab in Subjects With HER2-positive Unresectable Locally Advanced or Metastatic Gastroesophageal Adenocarcinoma (GEA)
Enrollment Status: Active_not_recruiting
Publish Date: September 01, 2026
Intervention Type: Drug
Study Drugs: Zanidatamab, Tislelizumab, Trastuzumab, Capecitabine, Oxaliplatin, Cisplatin, 5-Fluorouracil
Study Phase: Phase 3

29 Total Publications

Integrated bulk RNA-seq and scRNA-seq identification of a novel "PET-SPI1-MYL9" transcriptional axis in lung adenocarcinoma driven by polyethylene terephthalate exposure.
Integrated bulk RNA-seq and scRNA-seq identification of a novel "PET-SPI1-MYL9" transcriptional axis in lung adenocarcinoma driven by polyethylene terephthalate exposure.
Journal: Translational cancer research
Published: November 25, 2025

Frequently Asked Questions about Xiaoming Hou

Is Xiaoming Hou a top-rated expert for Bile Acid Malabsorption?

MediFind is an objective health platform that identifies experts based on real-world data. Xiaoming Hou is classified as an Experienced expert for Bile Acid Malabsorption, meaning they are among the top experts in the country for this condition. This ranking is based on their volume of patients, published research, and peer connections.

Does Xiaoming Hou participate in research or clinical trials?

Yes. Xiaoming Hou has published 29 articles and abstracts on conditions like Bile Acid Malabsorption. You can view a list of Xiaoming Hou's latest peer-reviewed publications and clinical trial participation on their profile to see if they are active in new treatments.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Hou's expertise for a condition
ConditionClose
        View All 7 Experienced Conditions
        Want to save this expert for later?
        Sign Up
        Not sure about your diagnosis?
        Check Your Symptoms
         
         
         
         
        Learn about our expert tiers
        Learn More
        Are you the provider on this profile?
        Claim Profile